This opportunity is no longer accepting applications.
grant PAR-22-131

Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)

This grant opportunity aims to support cutting-edge projects focused on integrating various advanced technologies like imaging, biomarkers, and omics data to improve cancer detection and diagnosis. The goal is to enhance the ability to detect aggressive cancers early and identify potentially deadly precancerous lesions. The technology integration may involve AI or virtual reality for improved …

This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diag…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Cancer Institute
Program: SBIR

Dates

Opportunity Released: April 12, 2022
Open for Submission: April 12, 2022
Submission Deadline: September 7, 2025
Application Window Closes: September 7, 2025

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.